EuBiologics
Key metrics
Earnings
| Revenue, Q3 2026 | ₩49.6bn |
|---|---|
| Revenue QoQ | Not available |
| Revenue YoY | Not available |
| Operating income, Q3 2026 | ₩21.9bn |
| Operating income QoQ | Not available |
| Operating income YoY | Not available |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | Not available |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | Not available |
| Treasury shares cancelled, last 3 months | ₩4.5bn |
| Treasury shares cancelled (number), last 3 months | 398,987 shares |
| Treasury shares cancelled, last 3 months, % of shares | Not available |
| Buyback decided, last 12 months | ₩6.0bn |
| Buyback decided, last 12 months, % of shares | Not available |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | Not available |
| Treasury shares cancelled, last 12 months | ₩4.5bn |
| Treasury shares cancelled (number), last 12 months | 398,987 shares |
| Treasury shares cancelled, last 12 months, % of shares | Not available |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | Not available |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩79.6bn |
|---|---|
| Supply contracts vs prior-year revenue | 53.3% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 4 |
|---|---|
| DART filings, previous 3 months | 14 |
Insider transactions
| Open-market buys, last 12 months (shares) | 369,627 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩5.1bn |
| Open-market sells, last 12 months (shares) | 685 shares |
| Open-market sells, last 12 months (amount) | ₩9m |
| Net open-market buying, last 12 months (shares) | 368,942 shares |
| Insiders who bought, last 12 months | 4 |
Insider transactions (last 12 months)
Open-market buys: 369,627 shares (₩5.1bn). Open-market sells: 685 shares (₩9m). Net open-market buying: +368,942 shares. Insiders who bought: 4.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Heo Tae-yeong (Registered director) | Open-market buy | +2,000 shares | ₩8,590 | ₩17m | |
| Jul 3, 2026 | Heo Tae-yeong (Registered director) | Open-market buy | +1,000 shares | ₩8,770 | ₩9m | |
| Jul 2, 2026 | Heo Tae-yeong (Registered director) | Open-market buy | +6,000 shares | ₩8,620 | ₩52m | |
| Apr 28, 2026 | Shin Yeong-hui (Non-registered officer) | Open-market sell | -685 shares | ₩13,640 | ₩9m | |
| Apr 21, 2026 | Shin Yeong-hui (Non-registered officer) | Open-market buy | +685 shares | ₩14,000 | ₩10m | |
| Apr 6, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +29,646 shares | ₩13,619 | ₩404m | |
| Apr 2, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +60,000 shares | ₩13,743 | ₩825m | |
| Apr 1, 2026 | Kim Rak-gi (Non-registered officer) | Other (New appointment) | +3,366 shares | — | — | |
| Mar 30, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +20,000 shares | ₩13,935 | ₩279m | |
| Mar 25, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +115,572 shares | ₩13,900 | ₩1.6bn | |
| Mar 24, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +25,000 shares | ₩14,159 | ₩354m | |
| Mar 23, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +15,000 shares | ₩14,218 | ₩213m | |
| Mar 20, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +10,500 shares | ₩14,268 | ₩150m | |
| Mar 18, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +19,428 shares | ₩14,465 | ₩281m | |
| Mar 16, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +10,000 shares | ₩14,830 | ₩148m | |
| Mar 13, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +10,000 shares | ₩14,877 | ₩149m | |
| Mar 12, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +14,000 shares | ₩14,274 | ₩200m | |
| Mar 11, 2026 | BioNote, Inc. (10%+ shareholder) | Open-market buy | +20,796 shares | ₩13,786 | ₩287m | |
| Jan 28, 2026 | Jeon Dong-un (Non-registered officer) | Other (Stock option exercise) | +10,000 shares | ₩6,440 | ₩64m | |
| Jan 28, 2026 | Shin Jeong-seop (Non-registered officer) | Other (Stock option exercise) | +10,000 shares | ₩6,080 | ₩61m | |
| Jan 28, 2026 | Jang Jae-seon (Non-registered officer) | Other (Stock option exercise) | +5,000 shares | ₩6,080 | ₩30m | |
| Jan 2, 2026 | Baek Yeong-ok (Registered director) | Open-market buy | +10,000 shares | ₩11,695 | ₩117m | |
| Nov 27, 2025 | Tae Yeong-jin (Non-registered officer) | Other (Stock option exercise) | +25,000 shares | ₩6,440 | ₩161m |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩149.2bn | ₩60.7bn |
| 2024 | ₩96.0bn | ₩34.3bn |
| 2023 | ₩69.4bn | ₩7.7bn |
Filing timeline
-
EuBiologics signs ₩10.5bn oral cholera vaccine supply contract with UNICEF
EuBiologics filed a supply contract to supply its oral cholera vaccine (Euvichol-S) to UNICEF, with a contract amount of ₩10.5bn. The contract period runs from Oct 23, 2026 to Jan 31, 2027, and the amount is 7.0% of revenue as reported.